Monoclonal antibodies and Fc fragments for treating solid tumors

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 13-20

  Eisenbeis, Andrea M ^a   Grau, Stefan J ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Biological therapy; Cancer; Monoclonal antibodies; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CATUMAXOMAB; CETUXIMAB; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FARLETUZUMAB; FLUOROURACIL; FOLINIC ACID; GIRENTUXIMAB; IMMUNOGLOBULIN FC FRAGMENT; INTERFERON; IPILIMUMAB; IRINOTECAN; LAPATINIB; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NECITUMUMAB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; PLACEBO; TAXANE DERIVATIVE; TEMOZOLOMIDE; TICILIMUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TREBANANIB; UNINDEXED DRUG; ZALUTUMUMAB;

ABDOMINAL PAIN; ACNE; BIOTECHNOLOGY; BREAST CANCER; COLITIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG APPROVAL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENDOCRINE DISEASE; FEVER; FLU LIKE SYNDROME; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG DISEASE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALAISE; MELANOMA; ONCOLOGY; OVARY CANCER; PATHOPHYSIOLOGY; PNEUMONIA; REVIEW; SIDE EFFECT; SKIN; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; WEAKNESS;

EID: 84856649117     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefned specifcity. Nature. 1975;256(5517):495-497.
2. Dillman RO. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm. 1999;14(1):5-10.
3. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med. 1989;111(7):592-603.
4. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol. 1994; 12(7):1497-1515.
5. Wigzell H. The immune system as a therapeutic agent. Sci Am. 1993; 269(3):126-134.
6. Boon T. Teaching the immune system to fight cancer. Sci Am. 1993; 268(3):82-89.
7. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354(11):1166-1176.
8. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med. 1992; 327(10):736.
9. Bajorin DF, Chapman PB, Wong GY, et al. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res. 1992;2(5-6):355-362.
10. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648.
11. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004;3(11): 1493-1501.
12. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/ neu-overexpressing metastatic breast cancer. Semin Oncol. 1999; 26(4 Suppl 12):78-83.
13. Schechter AL, Stern D F, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513-516.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
17. Heimann DM, Weiner LM. Monoclonal antibodies in therapy of solid tumors. Surg Oncol Clin N Am. 2007;16(4):775-792.
18. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
19. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
20. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-2550.
21. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-2676.
22. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605): 2103-2111.
23. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
24. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672-680.
25. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosen-sitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935-1940.
26. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010;10(1):80-95.
27. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
28. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14):1408-1417.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-578.
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28.
31. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multi-center phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-2177.
32. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005;41(2):107-127.
33. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorec-tal cancer. J Clin Oncol. 2007;25(13):1658-1664.
34. Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007;97(11): 1469-1474.
35. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fuorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4706-4713.
36. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
37. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-fnding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010;21(2):342-347.
38. Lacouture ME, Mitchell E P, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351-1357.
39. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-723.
40. ®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol. 2011; 29(1):121-126.
41. Machiels J P, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333-343.
42. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614-2627.
43. Ribas A, Hauschild A, Kefford A, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. 2008;26(20 Suppl): Abstract LBA9011.
44. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremeli-mumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010;16(3):1042-1048.
45. White A, Coleman R, Armstrong D, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive, relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol. 2010;28(15 Suppl): Abstract 5001.
46. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330-9336.
47. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010;2(2):129-136.
48. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162-171.
49. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009;69(14):5627-5629.
50. Carpenter G, Red BM. EpCAM: another surface-to-nucleus missile. Cancer Cell. 2009;15(3):165-166.